PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1529027
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1529027
Chemiluminescence Immunoassay Market, By Product (Instrument, Consumable, Reagent [Luminophore, Enzymatic Marker], Software & Service), Technology (CLEIA, ECLI), Sample Type, Application, End-use - Global Forecast 2024 - 2032
Global Chemiluminescence Immunoassay Market will witness a 7.3% CAGR between 2024 and 2032, driven significantly by the increasing number of product launches from leading companies. These launches are often characterized by innovative and enhanced assay kits that offer superior sensitivity, specificity, and faster turnaround times. Major players in the diagnostics industry are continuously investing in research and development to introduce next-generation CLIA systems that cater to the evolving needs of clinical laboratories and research institutions.
For instance, in January 2024, in a groundbreaking development for Indian healthcare technology, Agappe, a Kochi-based firm introduced its first indigenously manufactured HX series hematology equipment, along with the AI-powered Immunology CLIA analyzer, the Mispa i200. This marked the beginning of a new era in diagnostics and patient care.
These new products often incorporate advanced technologies, such as automation and multiplexing capabilities, which streamline laboratory workflows and improve efficiency. The introduction of portable and user-friendly CLIA devices has also expanded the market's reach, making these assays more accessible to smaller laboratories and point-of-care settings.
The overall Chemiluminescence Immunoassay Industry size is classified based on the product, technology, sample type, application, end-use, and region.
The chemiluminescence immunoassay (CLIA) market is experiencing increased demand driven by advancements in instruments. Modern CLIA instruments offer enhanced sensitivity, specificity, and efficiency, making them indispensable for clinical diagnostics and research. These instruments, characterized by their automation and high throughput capabilities, streamline laboratory workflows and provide rapid, accurate results. The integration of cutting-edge technologies, such as multiplexing and AI, in CLIA instruments has further broadened their application scope, from detecting infectious diseases to monitoring chronic conditions. As healthcare providers seek reliable and efficient diagnostic tools, the demand for sophisticated CLIA instruments continues to grow, propelling market expansion.
The chemiluminescence immunoassay (CLIA) market is significantly driven by the rising demand for electrochemiluminescence immunoassay (ECLIA) technologies. ECLIA offers superior sensitivity, specificity, and precision, making it a preferred choice in clinical diagnostics and research. This technology's ability to deliver rapid and accurate results is crucial for detecting various diseases, including infectious diseases and cancer. The automation and high throughput capabilities of ECLIA systems enhance laboratory efficiency and workflow. As the healthcare sector increasingly adopts advanced diagnostic methods for better patient outcomes, the demand for ECLIA continues to grow, contributing to the overall expansion of the CLIA market.
Asia Pacific chemiluminescence immunoassay (CLIA) market is experiencing significant growth, driven by advancements in healthcare infrastructure and increased demand for accurate diagnostic solutions. The rising prevalence of chronic and infectious diseases necessitates reliable and rapid testing methods, propelling the adoption of CLIA technology. Government initiatives and increased healthcare spending further boost the market, alongside growing awareness and adoption of advanced diagnostic tools. The region's expanding medical research and development activities also contribute to this surge. Consequently, the Asia Pacific CLIA market is poised for substantial expansion, driven by these healthcare advancements and increasing diagnostic needs.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360°synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of chronic and infectious diseases
- 3.2.1.2 Technological advancements in chemiluminescence immunoassay
- 3.2.1.3 Expanding applications in drug development and clinical research
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory scenario
- 3.2.2.2 High cost of devices
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.2.1 Automated
- 5.2.2 Semi-automated
- 5.3 Consumables
- 5.4 Reagents
- 5.4.1 Luminophore markers
- 5.4.2 Enzymatic markers
- 5.5 Software & services
Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Chemiluminescence enzyme technology (CLEIA)
- 6.3 Electrochemiluminescence immunoassay (ECLI)
- 6.4 Microparticle chemiluminescence immunoassay
Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Blood
- 7.3 Urine
- 7.4 Saliva
- 7.5 Other sample types
Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Therapeutic drug monitoring
- 8.3 Oncology
- 8.4 Cardiology
- 8.5 Endocrinology
- 8.6 Infectious diseases
- 8.7 Autoimmune diseases
- 8.8 Blood screening
- 8.9 Toxicology
- 8.10 Newborn screening
- 8.11 Metabolic disorder
- 8.12 Gastroenterology
- 8.13 Respiratory
- 8.14 Other applications
Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Hospitals
- 9.3 Clinical laboratories
- 9.4 Pharmaceutical & biotechnology companies
- 9.5 Other end-users
Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
- 11.1 Abbott Laboratories
- 11.2 Bio-Rad Laboratories, Inc.
- 11.3 Danaher corporation
- 11.4 DiaSorin S.p.A
- 11.5 Eurofins Scientific SE
- 11.6 F. Hoffmann-La Roche Ltd
- 11.7 H.U. Group Holdings, Inc.
- 11.8 Maccura Biotechnology Co., Ltd.
- 11.9 Revvity, Inc.
- 11.10 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 11.11 Shenzhen New Industries Biomedical Engineering Co., Ltd.
- 11.12 Siemens Healthineers AG
- 11.13 Thermo Fisher Scientific Inc.
- 11.14 Tosoh Corporation
- 11.15 Werfen
